My ePortfolio Register   

WIN Symposium 2017 /
Novel models to personalise cancer therapeutics

26th - 27th Jun 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.07.17
Views: 172

Dr Olli Kallioniemi - Karolinska Institutet, Stockholm, Sweden

Dr Kallioniemi speaks with ecancer at WIN 2017 about his research in developing targeted therapies for leukaemias, among other diseases.

He describes the need for data integration into healthcare processes to deliver significant, actionable data within a useful time frame, and how serial biopsies can undermine any resistance mutations as they arise.

Dr Kallioniemi notes the repositioning of axitinib for drug resistant leukaemia based on drug resistance as an example of how screening of tumours can inform treatment selection, foregoing the regulatory hurdles of developing a new therapy.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence